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Effects of ozone depletion not
limited to skin cancer
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Ultraviolet radiation suppresses immune
system, laboratory studies show
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Environment

Margaret L. Kripke,
chairman of the
Department of
Immunology, is presidentelect of t he American
Association for Cancer
Research . She will assume
the presidency in May of

1993

A thin layer of ozone in the stratosphere protects
us from 90% of the sun's ultraviole( (UV) B
radiation, the biologically active portion of the UV
spectrum. This layer has been the subject of much
debate since 1974, when researchers first proposed
that it could be diminishing.
"A lot of effort has been spent trying to verify
ozone depletion," said Margaret L. Kripke, Ph.D.,
chairman of the Department of Immunology at
The University of Texas M. D. Anderson Cancer
Center. "But now we're fairly confident that
changes are occurring in the ozone layer." As a
result, research on the effects of these changes is
becoming more important.
"Life on earth has evolved to cope with a very
small ;amount of UV light," Kripke said. "If there
is a sudden, substantial increase in the amount of
UV light in sunlight, then people, plants, and
animals won't have an opportunity to evolve
protective mechanisms." Changes in growth and.
photosynthesis could have significant effects on
crops, ecosystems (and thus biological diversity),
and phytoplankton (the base of the whole marine
food chain), a variety of studies have suggested.
Increased UV radiation is also expected to result in
increased incidence of skin cancer, melanoma, and
cataracts, Kripke said.
However, immune suppression as a result of UV
radiation could have the broadest implications of all.
Kri.pke, a pioneer of the field of photoimmunology,
has shown that the UV radiation in sunlight not
only can induce skin cancer, but also can weaken
our immune systems, making us more vulnerable
to the carcinogenic process and, perhaps, to
infectious diseases.
"The world's two major health problemsstarvation and infectious disease-kill more people
than cancer, war, or anything else," Kripke
commented. "Ozone depletion could aggravate

both problems: one by affecting the food chain and
the other by affecting the immune system."
Texans could be particularly affected, for three
reasons. First, we get large doses of UV radiation
because of our geographical location. Second, many
Texans have outdoor occupations, such as jobs in
oil fields, on ranches, and in the shipping industry.
Finally, a lot of immigrants from Wales, England,
and Germany settled in Texas, and many of these
families have very poor protective mechanisms
against sun damage, Kripke said. Although the
darker skin of blacks and Hispanics protects them
somewhat from the carcinogenic effects of UV
radiation, a study by University of Miami researcher
Dr. Martin Vermeer and colleagues has suggested
that pigment does not protect against
immunological effects.
Predicting the impact on local and world health
of increased UVB radiation will require a substantial
research effort. Kripke is working to answer two
fundamental questions: (1) what are the molecular
and cellular events involved in UV-induced immune
suppression and (2) do these events make an
organism more susceptible to infection?

How does UV radiation lead to immune suppression?
Kripke is studying the first question from three
different angles: the activation of the suppressive
immune pathway, the molecular target of UV
radiation, and the role of chemical mediators
released from the irradiated cells.
"The immune system has an active pathway and
a suppressive pathway," Kripke said. When the
active pathway is triggered, an immune response
occurs. When the suppressive pathway is triggered,
however, suppressor T lymphocytes are produced,
which turn off the immune response. Kripke has
shown that UV irradiation causes the immune
continued on page 2
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"Changing public behavior
will be very important in lessening the
eventual clinical impact of ozone
depletion"
•

•

•

system to shift from the active to the suppressive
pathway. For example, if the immune system is
working correctly, then when a chemical like 2,4dinitrofluorobenzene (DNFB) is painted on mouse
skin, the skin becomes inflamed as phagocytic and
lytic cells move to the vicinity. However, this
contact hypersensitivity (CHS) response does not
occur if the mice are first UV irradiated; that is,
the normal immune response is suppressed. Kripke
is working on several projects to determine how
this shift from the active to the suppressive pathway
occurs. Recent studies in her laboratory have
focused on Langerhans cells, which carry antigen
molecules to the lymph nodes and bind with T
lymphocytes to induce the CHS response. Results
suggest that the Langerhans cells, which are altered
by UV radiation, are involved in the shift to a
suppressive pathway.
A second area that Kripke is focusing on is the
initial molecular target of UV radiation. She
hypothesized that DNA damage induced by UV
radiation triggers the immunosuppressive process.
To test this hypothesis, she irradiated mice with
UVB light, then treated them with liposomes
designed to degrade when taken up by skin cells,
releasing a DNA repair enzyme. She then

•

•

•

•

immunized the mice with the chemical D NFB.
Kripke found that they displayed a normal inflammatory
response to DNFB even though they had been
irradiated. In other words, CHS suppression was
avoided because UV-induced DNA damage was
repaired by the enzyme. It is possible that this liposome
approach could one day be used therapeutically to
repair DNA damage in humans.
A third aspect of Kripke's studies of the cellular
events of UV-induced immune suppression regards
the role of cytokines, immunologically active
mediators. Jorge M. Rivas and Stephen E. Ullrich,
Ph.D., her coworkers in the Department of
Immunology, recently discovered that interleukin10 is one of the immunosuppressive cytokines
released in UV-irradiated murine skin cell cultures.
Although such mediators have immunosuppressive
effects at certain concentrations, many have
beneficial biological effects at other concentrations,
Kripke said. Such beneficial effects may be the
reason that a connection between UV radiation
and immune suppression was selected during the
course of evolution. "It doesn't sound very logical
that when you go out into the sun, your immune
system is suppressed," Kripke said . "But there must
be a benefit at some UV dose."
Does immune suppression promote infection

Why Texans Should Be
Concerned about UV Radiation
• Geography. Southern regions receive
higher doses of UV radiation
• Outdoor occupations. Many Texans
work outdoors in oil fields, ships,
ranches, and farms

• Ethnic background.Texas descendants
of fair-skinned immigrants from Wales,
England, and Germany are particularly
vulnerable to UV radiation

by pathogens?
"We know from studies done by other groups
that the situation in humans is very similar to what
we've observed in the mouse," Kripke said. "The
human immune system is diminished in some ways
by UV radiation. But we don't yet know whether
that's important for infectious disease processes."
To answer this question, Kripke's laboratory is
studying the effects of UV radiation on the
immunity of mice to several infectious diseases.
During the last five years, she and colleague
Amminikutty Jeevan, Ph.D., have studied most
extensively mycobacteria, the organisms that cause
tuberculosis and leprosy in humans. They found
that UV radiation does decrease the immune
response in acute and chronic infections by these
bacteria. Irradiated animals have a reduced ability
continued on page 7
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The physidan as sdentist
MIL

J fREIREICH, M.D., HAS LED A DISTINGUISHED CAREER AS A PHYSICIAN CONDUCTING BASIC CLINICAL

RESEARCH. FROM
TUTES OF HEALTH
RESEARCH. IN

1965,

1955

(NIH),

TO

1965, AT THE NEWLY FORMED

Interview

CLINICAL CENTER OF THE NATIONAL INSTI-

HE AND HIS COLLEAGUES MADE SEVERAL ADVANCES IN CHILDHOOD LEUKEMIA

HE CAME

rn THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, WHERE HE

TURNED TO THE STUDY OF ADULT LEUKEMIA. fREIREICH'S WORK, A BLEND OF CLINICAL CARE AND SCIENCE, HAS
ALWAYS BEEN GUIDED BY RIGOROUS SCIENTIFIC PRINCIPLES. HE TERMS THIS APPROACH BASIC CLINICAL RESEARCH, AND T HE PERSON WHO CONDUCTS SUCH RESEARCH IS A CLINICAL INVESTIGATOR. TODAY, fREIREICH
SEES FEWER AND FEWER YOUNG PHYSICIANS CHOOSING THIS TYPE OF RESEARCH AS A VOCATION, SO FEW THAT
HE CONSIDERS IT A CRISIS. H E HAS PARTICIPATED IN AN

51:753, 1991),

NIH

WORKSHOP EXAMINING THIS ISSUE ( LlNCER

AND HE HAS CONDUCTED HIS OWN STUDY OF IT

IN AN INTERVIEW WITH 0NCOLOG's MANAGING EDITOR,

KEVIN

U NATL

UNCER INST

R£s

83[12]:829, 1991).

FLYNN, fREIREICH DESCRIBES THE CRISIS AND

PROPOSES SOLUTIONS.

Q
Distinguish basic clinical research from research
in general. What's unique about it?
A
Basic clinical research links the laboratory with
the bedside, and the clinical investigator is the
interface between the clinic and the laboratory. He
or she is a doctor who not only treats a cancer
patient but also does research while treating a
cancer patient. When I go to the clinic and see a
leukemia patient, I'm doing research. I'm looking
at that person and saying, "Here's a treatment that
works in 75% of the people; why isn't it working
in you?" One of my patients was a 19-year-old
woman with leukemia who received three of the
best treatments we've discovered over the past 40
years. None worked. The job of the clinical
investigator is to find out why, by first developing
a hypothesis and then devising a study according
to rigorous scientific principles. To do so, clinical
investigators need to be trained in the methods of
science.
When I speak of the need for scientifically trained
clinical investigators, I don't mean to minimize
what basic scientists contribute to biology. I believe
strongly that the fundamental knowledge that
comes out of the laboratory is vital to progress in
medical research, but we also need a special type of
investigator who can commute successfully
between the lab and the bedside. Without this

Emil J Freireich is director
of the Adult Leukemia
Research Program in
the Department of
Hematology. In 1990, he
was the first recipient of the
NIH Distinguished Alumni
Award

kind of investigator, the valuable insights that basic
scientists provide cannot be optimally translated
into practice. Biomedical research is growing faster
than we can apply it, and part of the problem is
that the clinical investigator is a species that is
dying.

Q
Why?
A
There are two reasons: First, it is very lucrative
for physicians to work in other fields of medicine.
A young physician who goes into emergency
medicine or diagnostic radiology can make a sixfigure income in the first year. Second, the grant
application process is highly competitive. Only 15%
of all grants are funded. It takes a lot of work to
apply for grants and succeed. Combined, these
two factors provide a powerful disincentive against
choosing basic clinical research as a discipline.
I've traveled to the 20 leading cancer centers to
see what was coming up from below, to see
whether young, bright people were interested in
being clinical investigators. When Dr. Tom Frei
and I came to M. D. Anderson in 1965, we were
probably 38 or 39 years old. [ Dr. Frei left M D.
Anderson in 1972 to go to the Dana-Farber Cancer
Institute) where he was physician in chief until
1992. -Ed.] Where are the 40 year olds coming
into this field? There are very few. Frei has seen
continued on page 4
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-'The crisis, today, is that there
are insufficient funds to support the
full-time clinical investigator"
•

•

•

the same thing. Our generation of clinical
investigators is not being replaced. I believe we
are at a crisis point. We need a major paradigm
shift, a new way of thinking about the place of
basic clinical research in medicine. Dr. Frei and I
recently submitted an editorial on this topic.

Q
Talk about the first generation of clinical
investigators. Why did you enter this field?

A
In 19 5 5, I was a young scientist in training at
Boston University. Dr. Chester Scott Keefer, dean
of the Boston University School of Medicine,
called me into his office. Keefer was the first
assistant undersecretary for health affairs,_jp the
Eisenhower administration. Apparently, he had
heard of open positions at NIH and thought I
would qualify. Keefer said, "Freireich, have you
ever heard of the National Institutes of Health?"
I said, "No sir." He said, "Well, there's this new
place in Bethesda. I want you to go look at it." I
said, "Yes sir." If he told me to jump out the
window, I would have done it. So I got in my
car, went to Bethesda, and got the job.
The place was about 20% occupied, so I got an
entire floor. Those were times of great affluence.
What happened at that time, in 1955, was the
beginning of this discipline called clinical research.
The NIH was a revolution in research. It was
designed to allow investigators to study medicine
scientifically. This idea is commonplace today, but
when I was in medical school we debated whether
medicine was a science or an art. In 1955, the
NIH was just a bunch of young lab scientists and
physicians learning science. They were given
unlimited resources, and in a decade American
medicine was changed forever. From this one little
building in Bethesda poured revolutionary
advances in cancer and heart disease treatment,
among others.

Q
It seems that this approach was successful. If
such was the case, what led the scientific

•

•

•

community away from it?

A
All paradigms have a natural history. You choose
a paradigm, or method of operation, because it's
successful, and its success encourages you to
continue using the same paradigm. This is precisely
what happened with our national research funding
system. We were getting tremendous progress out
of basic science, so we diverted an increasing
proportion of money into basic science research.
That was perfectly logical, but this approach
becomes rate-limiting if no clinical investigators
are available to bring the lab work to the bedside.
The crisis, today, is that there are insufficient funds
to support the full-time clinical investigator. The
crisis, though, was not caused by a idck of vision
on anybody's part. The current system has led to
enormous breakthroughs, but we need to find a
way to let all this basic science knowledge flow
through, from the laboratory to the clinic. The old
paradigm is depleting itself

Q
What's the solution?

A
Dr. Frei and I propose three things. The first is
to create a professional society, to ensure that basic
clinical research is recognized as a unique discipline
and to build an esprit de corps.
Second, all medical schools should create a threetrack tenure system for physicians. Most schools
have a two-track system, one track for physicians
who stay in the clinic and don't do research, and
one for full-time laboratory people. Well, why not
have a clinical research track for clinical investigators?
The secret to having a clinical research track is to have
a tenure and promotions committee run by clinical
investigators and to provide full academic privileges.
This would restore the clinical investigator's
credibility in the academic community by creating
a peer review system for them (for tenure).
And third, we just have to face it: there has to be
a study section at NIH run by clinical investigators,
people who recognize the realities of clinical
continued on page 7
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'-The goal ... is to establish
a network for collaborative research
between M. D. Anderson ... and
community investigators~
•

•

Physician Network
continued from page 8

a request for proposals to hospital-based oncology
programs and o ncologists and hematologists
throughout the state. The respondents within each
community were encouraged to form consortia of
their institutions so that they could meet the minimum requirement of 800 to 1000 cancer cases per
year. The applicants also had to demonstrate that
they were capable of organizing and maintaining a
consortium and that they had successfully participated in clinical trials and community-based research.
Of the 11 consortia that applied, six were accepted,
and the network officially began in July 1992. The
six consortia, which comprise 16 institutions, are
located in Dallas, Fort Worth, Houston, Lubbock,
Temple, and Tyler. The consortia in Dallas and
Houston include only certain private hospitals,
wher,eas those in the other cities represent all of
the major facilities in the area, both public and
private, that provide oncology services. The Texas
Outreach Program funds a research nurse/data
manager, a health services coordinator, and a
research assistant at each of the six lead sites. Most
of the data management and analysis is centralized
in the Section of Community Oncology at M. D.
Anderson, taking advantage of a system that was
already in place as part of the Community Clinical
Oncology Program ( CCOP), a nationwide
cooperative of 35 consortia funded by the National
Cancer Institute (NCI). W mn is also the director
of the M. D. Anderson CCOP research data base.
Philip A. Salem, M.D., is director of the Cancer
Research Program at St. Luke's Episcopal Hospital
in Houston and leader of the Houston TCON
consortium. To him, "TCON is the ideal model
of cooperation between the comprehensive cancer
center and the community hospitals because it is
complementary and mutually beneficial. Patients
can participate in beneficial research protocols while
remaining in familiar surroundings, and M. D.
Anderson is able to accrue larger numbers of
patients into its protocols."

•

•

•

•

Seventeen protocols are available to network
participants
The cancer patients seen by network physicians
represent from 10% to 17% of the estimated
number of cases in Texas; the most prevalent
cancers, such as those of the breast, lung, colon,
and prostate, are well represented. After the
participating institutions were selected, the first task
was getting their institutional review boards (IRBs)
to approve their participation in the clinical trials.
These approvals have now been obtained, said
Wmn, and physicians from these institutions have
begun recruiting their patients for the TCON
clinical trials, which will eventually include many
of the protocols active at M. D. Anderson. Right
now about 15 protocols have been approved and
are available to TCON patients, and many more
will soon become available. Said Wmn, "We have
obtained permission from the NCI to use some of
its protocols for TCON, and we are working with
several pharmaceutical companies to provide
experimental drugs for TCON protocols."
Network makes study of rare diseases easier
TCON is particularly suited to the study of rare
diseases. Even though M. D. Anderson has a large
patient population, said Wmn, "There are a lot of
rare diseases that even M. D. Anderson physicians
don't see enough of to conduct proper clinical
trials. These TCON patients will allow us to eclarge
these trials, enhancing the validity of the results.
Participation in the TCON trials also benefits the
patients. Many patients suitable for protocols (that
is, patients having received no prior therapy) stay
in their communities and don't get entered into
protocols. By the time they come to M. D.
Anderson, they are getting their second or third
line of treatment and can't be put on most
protocols. With TCON, these patients can be
placed on protocols right away, giving both us and
the patient a great advantage."
TCON patients, if eligible, may also participate
in chemoprevention trials, in which mild, relatively
nontoxic agents, such as vitamin A and E
derivatives, are administered regularly in an attempt
to prevent certain cancers in those at high risk of
continued on page 6
pages
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"Patients can participate
in beneficial research protocols
while remaining in familiar
surroundings~
•

•

developing them. These trials are testing these
agents in persons who have already had certain
types of cancer and are therefore at risk for a second
or third cancer. Trials of chemoprevention of head
and neck, lung, and colon cancer are now available
to TCON patients. Said Salem, "TCON provides
a mechanism for placing healthy people at high
risk of developing cancer in these very promising
chemoprevention studies."
TCON physicians have on-line access to M. D.
Anderson
Physicians participating in TCON learn about
the protocols available to their patients via a
computer system called TRON. Physicians can use
their own computers to connect with TRON,
which features a detailed data base of all M. D.
Anderson protocols and a bulletin board that
TCON physicians can use to ask questions of M. D.
Anderson physicians. Because of funding
limitations, TRON is currently available only to
TCON physicians, but eventually TCON
administrators would like to make it more widely
available.

Objectives of the Texas
Community Oncology Network
• to conduct clinical trials of new
therapies
• to launch large chemoprevention
trials
• to conduct health services research
• to use modern communication
technologies to share information
among network participants

page6
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The TCON network has also begun its first
health services research project. The overall
objective is to characterize the factors affecting the
use of medical resources by women who died of
metastatic breast cancer. The researchers are
examining data on their diseases and treatments,
the characteristics of their physicians and the centers
where they received care, and the availability of
support services in their counties of residence. They
are gathering these data in an attempt to discern
patterns and variations in the care these women
received. From this study they hope to develop
hypotheses about patient, physician, and hospital
characteristics that determine the choice of therapy;
these hypotheses will then be tested in a follow-up
study of a group of living women with breast
cancer. The follow-up study will attempt to
document the sequence of decision-making events
in the treatment process and will allow a better
understanding of the variations in care and of the
impact that these have on costs and outcomes.
Said Salem, "This program promot es
communication and cooperation between research
institutions and many community hospitals, and
TCON is helping to break down that wall. Any
physician in any practice setting can participate in
research. Many of the physicians who've made
important contributions to cancer research were
not full-timers at a major research institution."
Winn concurred, "We know the community
oncologists can do research; they all train in
universities, where they are involved in research,
before they go out into the community. What we
have built for them is the structure they need to
perform research. By participating in these clinical
trials, they are able to give their patients new
experimental therapies in their home towns without
ever coming to M. D. Anderson."
-KATHRYN L. HALE
Physicians who desire additional information may
write Dr. Winn, Section of Community Oncology,
Box 501, The University of Texas M. D. Anderson
Cancer Center, 1515 Holcombe Blvd., Houston,
Texas 77030, or call (713) 792-8515.
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UV Radiation
continued from page 2

to clear the bacteria from their lymphoid tissues,
so the course of the disease is prolonged. UV
radiation can actually accelerate death from chronic
mycobacterial infection.
Kripke's group is also looking at how UV
radiation affects Lyme disease, schistosomiasis, and
infections caused by the opportunistic fungus
Candida albicans. They have found that UVirradiated mice have a reduced immune response
to C. albicans compared with both unirradiated
mice and irradiated mice treated with liposomes
containing a DNA repair enzyme.

Education will lessen clinical impact of ozone
depletion
In all of these studies, the doses of UV light
given mice are comparable to the amount of natural
UV light many humans are exposed to. "We are
not using megadoses," Kripke said. One or two
UV treatments causing minimal redness induce
systemic immune suppression. In fact, in a recent
study of sunscreen effectiveness, Peter Wolf, M.D .,
Cherrie K. Donawho, Ph.D., and Kripke found
that it took more UV light to give a mouse a
sunburn than it did to induce immune system
alterations. Their findings raised the concern that
sunscreens may not protect against the immunological effects of UV radiation. "Sunscreens may give us a
false sense of security," Kripke said. People who stay
outside longer with the help of sunscreens may actually be getting more immunosuppressive UV light
than they would otherwise.
Issues like these highlight the need to clarify the
immunosuppressive effects of UV radiation. "We
also need to educate people to protect themselves
from excessive exposure," Kripke said. In particular,
patients who are taking immunosuppressive drugs
or have had an organ transplant should avoid
sunlight, she noted. "And it's very important to
increase the awareness of protecting children. Most
UV exposure received in a lifetime occurs in
childhood, because children spend so much time
outdoors." There is some epidemiological evidence
that sunburns in childhood are predisposing factors
for development of melanoma later, Kripke said.
"Whether increased UV light in our environment
will affect the incidence of melanoma is fairly
controversial," Kripke said, "but we have found
that exposing mouse skin to UV light promotes
the growth of implanted melanoma cells."

Attitudes toward exposure to sunlight are changing in at least a segment of the population, Kripke
notes. Tanning is not as fashionable as it once was.
"But I'm not sure that people who work outdoors
have changed their lifestyles at all," she said.
"Changing public behavior will be very important
in lessening the eventual clinical impact of ozone
depletion."
-SUNITA PATTERSON

Physicians who desire additional information may
write Dr. Kripke at Box 178, The University ofTexas
M. D. Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, Texas 77030, or call (713) 792-8578.

Physician Scientists
continued from page 4

research. Funding agencies have to recognize that
a clinical investigator cannot spend all his or her
time in the laboratory, and he or she shouldn't
have to compete with those that do. First of all, if
you're going to do clinical research, it doesn't
exempt you from taking care of sick people. If you
want to treat four leukemia patients, you 're going
to be up all night, the family is going to call you
four times a day, and the patient is not going to
agree to every treatment you want to do. It's
complicated. It takes a lot of time, skill, knowledge,
and experience.

Q
If you wanted to convince medical students to
be clinical investigators, what would you tell
them?
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A
I would tell them that the only deficiency in
medicine is clinical research, and if I were young, I
would look for an area where there was very little
competition and lots of opportunity for the future.
The thing to remember, though, is that you have
to learn science but think like a physician. Some
questions only a clinical investigator can ask.
Physicians who desire additional information may
write Dr. Freireich, Department of Hematology, Box
55, The University of Texas M. D. Anderson Cancer
Center, 1515 Holcombe Boulevard, Houston, Texas
77030, or call (713) 792-2660.
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New physidan network brings M. D.

Anderson to local communities
Treatment Update

Rodger J. Winn is director
of the Community
Oncology Program. He is
also chairman of the
Ad Hoc Technology
Assessment Committee of
the American Society of
Clinical Oncology

Many cancer patients in Texas who want
aggressive, experimental care travel to The
University of Texas M. D. Anderson Cancer
Center in Houston. These travellers leave behind
families, friends, jobs, and communities in search
of the treatment that might make them well.
The journey often creates financial as well as
emotional hardships for the families, but they
are willing to take on those hardships, certain
that the newest and most effective therapies can
be had only at a large clinical research center
like M. D. Anderson Cancer Center.
A new program coordinated at M. D. Anderson,
however, is making it much easier for residents in
and near six communities in the state to get this
investigational treatment much closer to home. The
program, called the Texas Community Oncology
Network (TCON), has created a cooperative of
oncologists in these communities whose overall
mission is improving the care of cancer patients.

TCON is one of the 10 projects funded through
the T exas Outreach Program, an initiative that
began last year to expand and improve cancer
screening and prevention services to all Texas
residents. The program is funded by up to $15 million
in fees earned by M. D. Anderson physicians.

Involvement of local physicians is the goal
"The goal of TCON," said Rodger J. Wmn,
M.D., director of the program and head of the
Section of Community Oncolo gy of the Division
of Medicine, "is to establish a network for collaborative research between M. D. Anderson investigators and community investigators. We have four
specific aims: to do clinical trials of new therapies,
to launch large chemoprevention trials, to do what
is now generally called health services research, and
to use modern communication technologies to
share information aqiong network participants."
The network was created when Wmn's group sent
continued on page 5

